Drug Profile
EDP 239
Alternative Names: EDP239Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Enanta Pharmaceuticals
- Class Antivirals; Small molecules
- Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hepatitis C
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Hepatitis-C in Germany (PO)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Hepatitis-C in USA (PO)
- 01 Oct 2015 Enanta Pharmaceuticals completes a phase I trial in Hepatitis C in USA and Germany (PO) (NCT01856426)